HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2006.03.038v1 48/2/298    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Angiolillo, D. J. Articles by Fernandez-Ortiz, A. Search for Related Content PubMed PubMed Citation Articles by Angiolillo, D. J. Articles by Fernandez-Ortiz, A.

CLINICAL RESEARCH: DIABETES AND CARDIOVASCULAR DISEASE

Insulin Therapy Is Associated With Platelet Dysfunction in Patients With Type 2 Diabetes Mellitus on Dual Oral Antiplatelet Treatment

Dominick J. Angiolillo, MD, PhD, FACC^_*,1,_*, Esther Bernardo, BSc, Celia Ramírez, BSc, Marco A. Costa, MD, PhD, FACC^_*, Manel Sabaté, MD, PhD, Pilar Jimenez-Quevedo, MD, Rosana Hernández, MD, PhD, Raul Moreno, MD, Javier Escaned, MD, PhD, Fernando Alfonso, MD, PhD, Camino Bañuelos, MD, Theodore A. Bass, MD, FACC^_*, Carlos Macaya, MD, PhD and Antonio Fernandez-Ortiz, MD, PhD

^_* Division of Cardiology, University of Florida, Shands Jacksonville, Jacksonville, Florida
Cardiovascular Institute, San Carlos University Hospital, Madrid, Spain.

Manuscript received February 3, 2006; revised manuscript received March 10, 2006, accepted March 20, 2006.

^_* Reprint requests and correspondence: Dr. Dominick J. Angiolillo, Division of Cardiology, University of Florida, Shands Jacksonville, 655 West 8th Street, Jacksonville, Florida 32209. (Email: dominick.angiolillo{at}jax.ufl.edu).

OBJECTIVES: This study sought to assess the influence of type 2 diabetes mellitus (T2DM) and the impact of hypoglycemic treatment (insulin vs. noninsulin) on platelet function profiles in patients treated with dual oral antiplatelet therapy.

BACKGROUND: Insulin inhibits platelet aggregation by suppressing the P2Y₁₂ pathway. However, T2DM patients have a loss of responsiveness to insulin that leads to upregulation of the P2Y₁₂ pathway, increased platelet reactivity, and reduced responsiveness to antiplatelet agents. Patients with insulin-treated diabetes mellitus (ITDM) have a more advanced disease status and higher atherothrombotic risk compared with non-ITDM (NITDM). However, the impact of insulin therapy on platelet dysfunction in patients treated with P2Y₁₂ antagonists is unknown.

METHODS: A total of 201 T2DM and 65 nondiabetic patients with coronary artery disease in a steady phase of aspirin and clopidogrel treatment were studied. Platelet aggregation was assessed using agonists specific (6 and 20 µM adenosine diphosphate [ADP]) and nonspecific (6 µg/ml collagen and 20 µM epinephrine) for the P2Y₁₂ pathway. High shear-induced platelet reactivity was assessed by means of the PFA-100 system (Dade-Behring International, Miami, Florida).

RESULTS: The T2DM patients had platelet aggregation and shear-induced platelet function significantly increased compared with nondiabetic patients using all assays. Platelet aggregation was increased in ITDM (n = 68) compared with NITDM (n = 133) patients after P2Y₁₂-specific stimuli. Insulin treatment was the strongest predictor of ADP-induced aggregation. Platelet function profiles were similar between ITDM and NITDM using assays nonspecific to the P2Y₁₂ pathway. Platelet dysfunction was independent of glycemic control and inflammatory status.

CONCLUSIONS: The P2Y₁₂-dependent and -independent pathways of platelet reactivity are altered in T2DM compared with nondiabetic patients, and ITDM have greater ADP-induced platelet aggregation compared with NITDM.

Abbreviations and Acronyms   ADP = adenosine diphosphate   CADP = collagen/ADP   CEPI = collagen/epinephrine   CT = closure time   HbA1C = hemoglobin A1C   ITDM = insulin-treated diabetes mellitus   NITDM = noninsulin-treated diabetes mellitus   PPP = platelet-poor plasma   PRP = platelet-rich plasma   T2DM = type 2 diabetes mellitus

This article has been cited by other articles:

				D. J. Angiolillo, P. Capranzano, S. Goto, M. Aslam, B. Desai, R. K. Charlton, Y. Suzuki, L. C. Box, S. B. Shoemaker, M. M. Zenni, et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study Eur. Heart J., June 21, 2008; (2008) ehn287v1. [Abstract] [Full Text] [PDF]

				C. Manrique, G. Lastra, J. Palmer, M. Gardner, and J. R. Sowers Review: Aspirin and Diabetes Mellitus: revisiting an old player Therapeutic Advances in Cardiovascular Disease, February 1, 2008; 2(1): 37 - 42. [Abstract] [PDF]

				L. G. Mellbin, K. Malmberg, A. Norhammar, H. Wedel, L. Ryden, and for the DIGAMI 2 Investigators The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial Eur. Heart J., January 2, 2008; 29(2): 166 - 176. [Abstract] [Full Text] [PDF]

				D. J. Angiolillo, E. Bernardo, M. Sabate, P. Jimenez-Quevedo, M. A. Costa, J. Palazuelos, R. Hernandez-Antolin, R. Moreno, J. Escaned, F. Alfonso, et al. Impact of Platelet Reactivity on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease J. Am. Coll. Cardiol., October 16, 2007; 50(16): 1541 - 1547. [Abstract] [Full Text] [PDF]

				G. Campo, M. Valgimigli, D. Gemmati, G. Percoco, L. Catozzi, A. Frangione, F. Federici, F. Ferrari, M. Tebaldi, S. Luccarelli, et al. Poor Responsiveness to Clopidogrel: Drug-Specific or Class-Effect Mechanism?: Evidence From a Clopidogrel-to-Ticlopidine Crossover Study J. Am. Coll. Cardiol., September 18, 2007; 50(12): 1132 - 1137. [Abstract] [Full Text] [PDF]

				D. J. Angiolillo and F. Alfonso Clopidogrel Statin Interaction: Myth or Reality? J. Am. Coll. Cardiol., July 24, 2007; 50(4): 296 - 298. [Full Text] [PDF]

				G. J. Spalding, M. Hartrumpf, T. Sierig, N. Oesberg, C. G. Kirschke, and J. M. Albes Cost reduction of perioperative coagulation management in cardiac surgery: value of 'bedside' thrombelastography (ROTEM) Eur. J. Cardiothorac. Surg., June 1, 2007; 31(6): 1052 - 1057. [Abstract] [Full Text] [PDF]

				D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, T. A. Bass, and M. A. Costa Variability in Individual Responsiveness to Clopidogrel: Clinical Implications, Management, and Future Perspectives J. Am. Coll. Cardiol., April 10, 2007; 49(14): 1505 - 1516. [Abstract] [Full Text] [PDF]

				D. J. Angiolillo, S. B. Shoemaker, B. Desai, H. Yuan, R. K. Charlton, E. Bernardo, M. M. Zenni, L. A. Guzman, T. A. Bass, and M. A. Costa Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study Circulation, February 13, 2007; 115(6): 708 - 716. [Abstract] [Full Text] [PDF]

				A. J. Scheen and D. Legrand Platelet Dysfunction Associated With Insulin Therapy in Patients With Type 2 Diabetes: Please Do Not Throw the Baby Out With the Bathwater! J. Am. Coll. Cardiol., February 6, 2007; 49(5): 628 - 628. [Full Text] [PDF]

				D. J. Angiolillo, E. Bernardo, M. A. Costa, M. Sabate, T. A. Bass, C. Macaya, and A. Fernandez-Ortiz Reply J. Am. Coll. Cardiol., February 6, 2007; 49(5): 628 - 629. [Full Text] [PDF]

				T. Geisler, N. Anders, M. Paterok, H. Langer, K. Stellos, S. Lindemann, C. Herdeg, A. E. May, and M. Gawaz Platelet Response to Clopidogrel Is Attenuated in Diabetic Patients Undergoing Coronary Stent Implantation Diabetes Care, February 1, 2007; 30(2): 372 - 374. [Full Text] [PDF]

				A. J. Scheen and D. Legrand Aspirin and clopidogrel resistance in patients with diabetes mellitus Eur. Heart J., December 1, 2006; 27(23): 2900 - 2900. [Full Text] [PDF]

				F. Alfonso and D. J. Angiolillo Platelet Function Assessment to Predict Outcomes After Coronary Interventions: Hype or Hope? J. Am. Coll. Cardiol., November 7, 2006; 48(9): 1751 - 1754. [Full Text] [PDF]